E Novo Nordisk's Saxenda Approved But Company Enters Into A Crowded Obesity Market

Novo Nordisk should make some substantial revenue in the obesity space with Saxenda but it will take time as the space is already crowded by many players. Like all other obesity drugs Saxenda users must meet certain criteria to be able to qualify for a prescription of the drug by their doctors. The Body Mass Index - BMI - of the patient must be 30 or higher and for patients who have at least one other weight related condition. This could be like the conditions mentioned above - diabetes. It will be awhile until we see how an injection type obesity drug, performs in the market but one thing is clear: Saxenda (liraglutide) has already established a nice safety profile over many years compared to other obesity drugs, so it may have an advantage in future.

1 2
View single page >> |

Disclosure: No position in any stocks mentioned.

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Dick Kaplan 5 years ago Member's comment

Thanks, I've had my eye on this stock.